← Markets

Repligen Corporation

RGEN · NASDAQ

Market closed$147.25$-1.30 (-0.88%)After hours $147.25 · 0.00%

Key statistics

Previous close$148.55
Open$147.01
Day high$149.06
Day low$143.88
52-week high$175.77
52-week low$100.99
Market cap8.31B
Volume905.64K
Average volume1.14M
P/E ratio81.81
Forward P/E—
EPS1.80
Dividend yield0.00%

Market context

Why it moved

Repligen shares edged lower as the company's CFO sold shares under a pre-planned trading plan, signaling potential insider caution, while analyst sentiment noted the stock appears overvalued at current levels.

SteamdbInvesting.comIllinoistimesFacebookInstagram

What is happening

Recent company-specific developments and publisher coverage.

July 17, 2026Repligen closed modestly lower amid a broadly risk-off session, as tech and chip-sector weakness rippled through growth-oriented healthcare names. With Q2 2026 earnings scheduled for July 28, investors are closely watching for signs that the company's bioprocessing recovery — which saw Q1 revenue grow nearly 15% year-over-year to $194.3M — is continuing. Analyst sentiment remains cautiously optimistic, with a median price target of $160 versus the current trading level. UBS recently flagged life sciences tools as entering a new phase of earnings improvement, providing a constructive backdrop heading into results.

-0.8751

July 17, 2026Repligen Corporation edged higher, closing up modestly as investors look ahead to its Q2 2026 earnings report scheduled for July 28, with a conference call at 8:00 a.m. ET. The bioprocessing equipment maker posted 14.83% year-over-year revenue growth in Q1 2026 ($194.3M), and analysts carry a median price target of $160 — above current levels — with more institutional investors adding shares than reducing positions last quarter. In after-hours trading, shares extended gains, rising an additional 1.75% to $151.15, outpacing the healthcare sector ETF (XLV), which dipped slightly in extended hours amid a broadly constructive backdrop lifted by UnitedHealth's strong Q2 beat and raised guidance.

0.3309

July 16, 2026Repligen Corporation edged up modestly, outperforming some healthcare peers as the company announced its Q2 2026 earnings release date of July 28, putting results squarely in focus for investors. The bioprocessing equipment supplier posted strong Q1 2026 revenue of $194.3M — up ~15% year-over-year — and raised full-year EPS guidance, with Wall Street analysts maintaining a median price target of $160. Broader tailwinds from UBS upgrading the healthcare sector and life science tools companies emerging from their inventory cycle added to constructive sentiment, even as sector peers like Abbott and Stryker faced pressure from mixed earnings and macro headwinds.

0.6321

July 15, 2026Repligen shares edged higher, outperforming the broader healthcare sector (XLV), as a cooler-than-expected June CPI report lifted sentiment across life sciences names. The bioprocessing equipment supplier continues to benefit from a recovering biopharma demand backdrop, with Q1 2026 revenue up 15% and raised full-year EPS guidance drawing attention from investors watching whether the bioprocessing cycle recovery has legs. Shares are also gaining traction as a beneficiary of a weaker U.S. dollar narrative, with roughly 35% of revenue tied to Europe and APAC.

1.553

July 14, 2026Repligen edged up modestly at the close but surged nearly 5% in after-hours trading, diverging sharply from the broader healthcare sector (XLV) which slipped after hours. The after-hours jump stands out against a challenging backdrop for life sciences tools companies, where investors have been weighing concerns over biotech funding conditions, product mix volatility, and index removals. Analysts note that Q1 2026 results showed improving revenue and net income with raised full-year EPS guidance, and the company is being highlighted as a potential beneficiary of anticipated Fed rate cuts, which could ease funding pressures for its biopharma customers.

0.4437

July 10, 2026Repligen closed modestly higher, buoyed by a recent Benchmark Co. upgrade to Buy with a $185 price target and growing conviction around a bioprocessing recovery — yet the stock continues to trade at a significant discount to that target. The upgrade follows Repligen's removal from multiple Russell growth indexes in late June, a structural shift that has weighed on sentiment and liquidity, while some analysts flag valuation concerns at roughly 67x forward P/E. Q1 2026 revenue growth of 15% and a firmer bioprocess backdrop provide fundamental support, but the debate between recovery optimism and stretched multiples remains central to the investment case.

0.2084

July 9, 2026Repligen surged nearly 5%, outpacing both the broader healthcare sector (XLV flat in after-hours) and the S&P 500, driven by a wave of bullish analyst activity. Benchmark upgraded the stock to Buy from Hold with a $185 price target, and Evercore ISI raised its target to $160, citing a firmer bioprocessing demand backdrop and confidence in Repligen's recovery trajectory. The upgrades come as Q1 2026 revenue grew 15% year-over-year and analysts project earnings to grow ~30% annually toward a 2029 revenue target of $1.1 billion, though the stock's removal from multiple Russell Growth indexes in late June had weighed on near-term sentiment and passive fund flows.

4.7522

July 8, 2026Repligen closed modestly lower as broader market risk-off sentiment weighed on equities following President Trump's declaration that the U.S.-Iran ceasefire deal was 'over,' sending oil prices surging 5%+ and triggering a global selloff. The decline came despite a pair of constructive analyst developments: Benchmark upgraded RGEN to Buy from Hold with a $185 price target on July 7, and Evercore raised its target to $160 while maintaining an Outperform rating. However, headwinds persist — Repligen was removed from multiple Russell Growth indexes on June 27-29, which may pressure passive fund flows, and a recent analysis flagged the stock's 67x forward P/E and 16% six-month underperformance vs. the S&P 500 as concerns.

-1.7307

Simply Wall Street · July 16, 2026Repligen (RGEN) Stock May Trade At Fair Value But At A Sales PremiumQuiver Quantitative · July 15, 2026Repligen Corporation to Report Second Quarter 2026 Financial Results on July 28, 2026GlobeNewswire · July 15, 2026Repligen to Report Second Quarter 2026 Financial Resultsad-hoc-news.de · July 9, 2026Repligen stock trades steadily as bioprocessing demand shapes investor focusMoomoo · July 6, 2026Evercore Maintains Repligen(RGEN.US) With Buy Rating, Raises Target Price to $160Bloomberg.com · June 26, 2026Biolife Is Said to Have Drawn Takeover Interest From RepligenInvesting.com · May 14, 2026Repligen stock coverage resumed at RBC with outperform rating
Benzinga · July 7, 2026Benchmark Upgrades Repligen to Buy, Announces $185 Price Target
Mt Newswire · July 7, 2026Benchmark Upgrades Repligen to Buy From Hold, Price Target is $185
Benzinga · July 6, 2026Evercore ISI Group Maintains Outperform on Repligen, Raises Price Target to $160
Benzinga · June 3, 2026HSBC Maintains Buy on Repligen, Lowers Price Target to $150
Benzinga · June 2, 2026Wolfe Research Assumes Repligen at Outperform, Announces Price Target of $145
Mt Newswire · May 15, 2026Repligen Likely to Benefit From Diverse Growth Factors, RBC Says
Benzinga · May 15, 2026RBC Capital Reinstates Outperform on Repligen, Announces $160 Price Target
Benzinga · May 6, 2026JP Morgan Maintains Overweight on Repligen, Lowers Price Target to $165

Peers

S&P 500SPX · $7,457.69-1.01%Bio-Techne CorporationTECH · $72.12+0.49%Agilent Technologies, Inc.A · $131.46-3.41%Bio-Rad Laboratories, Inc.BIO · $304.36+1.12%Danaher CorporationDHR · $203.83-0.58%Thermo Fisher Scientific Inc.TMO · $532.48-1.97%Avantor, Inc.AVTR · $11.07-1.69%Charles River Laboratories International, Inc.CRL · $224.35-2.10%Sartorius Stedim Biotech S.A.SRTOY · $21.24+0.21%Qiagen N.V.QGEN · $41.15-0.87%Waters CorporationWAT · $368.98-2.44%Mettler-Toledo International Inc.MTD · $1,310.02-1.88%